SE0101328D0 - Therapeutic treatment - Google Patents

Therapeutic treatment

Info

Publication number
SE0101328D0
SE0101328D0 SE0101328A SE0101328A SE0101328D0 SE 0101328 D0 SE0101328 D0 SE 0101328D0 SE 0101328 A SE0101328 A SE 0101328A SE 0101328 A SE0101328 A SE 0101328A SE 0101328 D0 SE0101328 D0 SE 0101328D0
Authority
SE
Sweden
Prior art keywords
patients
therapeutic treatment
heart
treatment
infarctionpatients
Prior art date
Application number
SE0101328A
Other languages
Swedish (sv)
Inventor
Christina Abrahamsson
Tottie Nordlander
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101328A priority Critical patent/SE0101328D0/en
Publication of SE0101328D0 publication Critical patent/SE0101328D0/en
Priority to PCT/SE2002/000729 priority patent/WO2002083137A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The use of NPY Y2 receptor antagonists for the prevention of sudden death due to cardiac arrhythmias in patients in need of such treatment, for example post myocardial infarctionpatients, patients with heart failure and patients with disturbed electrical stability of the heart.
SE0101328A 2001-04-12 2001-04-12 Therapeutic treatment SE0101328D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0101328A SE0101328D0 (en) 2001-04-12 2001-04-12 Therapeutic treatment
PCT/SE2002/000729 WO2002083137A1 (en) 2001-04-12 2002-04-12 Use of npy y2 receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101328A SE0101328D0 (en) 2001-04-12 2001-04-12 Therapeutic treatment

Publications (1)

Publication Number Publication Date
SE0101328D0 true SE0101328D0 (en) 2001-04-12

Family

ID=20283784

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101328A SE0101328D0 (en) 2001-04-12 2001-04-12 Therapeutic treatment

Country Status (2)

Country Link
SE (1) SE0101328D0 (en)
WO (1) WO2002083137A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2020109546A1 (en) 2018-11-29 2020-06-04 University Of Copenhagen Treatment of cardiovascular diseases
CN111494606B (en) * 2020-04-24 2021-12-14 广州医科大学 New application of neuropeptide Y

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229283T2 (en) * 1991-11-06 1999-09-23 Garvan Institute Of Medical Research, Darlinghurst HUMAN NEUROPEPTIDE Y-Y1 RECEPTOR
SE9703414D0 (en) * 1997-09-23 1997-09-23 Astra Ab New compounds
DE19816929A1 (en) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma New amino acid derivatives useful as neuropeptide Y agonists and/or antagonists for treating cardiovascular disorders, coronary, cerebral or renal vasospasms, obesity, bulimia and asthma
EP1033366A3 (en) * 1999-02-18 2000-12-27 Pfizer Products Inc. Amide derivatives useful as Neuropeptide Y (NPY) antagonists

Also Published As

Publication number Publication date
WO2002083137A1 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
CY1116463T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
CL2008001932A1 (en) Compounds derived from 6-cycloamino-3- (pyridin-4-yl) imidazo [1,2-b] pyridazine, cq1epsilon and / or ck1delta inhibitors; preparation procedure; pharmaceutical composition comprising them; and use in the treatment of sleep disorders, circadian rhythm disorder, cancer, and Alzheimer's disease.
DE60040293D1 (en) USE OF NICOTIN IN THE ANGIOGENESIS AND THE VASCULOSIS
DE60226267D1 (en) DEVICE TO MINIMIZE VENTRICULAR REMODELING BY INFARCTION
BR0113643A (en) Guanidinobenzamides compounds as mc4-r agonists and their uses
AR025449A1 (en) PHARMACEUTICAL SOLUTIONS OF LEVOSIMENDAN
TR200002860T2 (en) New crystal forms of an antiviral benzimidazole composition.
BRPI0415709A (en) therapeutic regimens for baff antagonists
CY1108629T1 (en) Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart
PL404315A1 (en) A drug and pharmaceutical composition comprising 5-hydroxy-7-chloro-1-[2-methyl-4-(2-methylbenzoylamino) benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine for the treatment of severe heart failure and use thereof for the manufacture of a medicament
SE0101328D0 (en) Therapeutic treatment
EE05241B1 (en) Use of the α-halogenoacryl derivative of distamycin
DE60204694D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF HEART FAILURE
EE9900278A (en) Angiotensin II antagonists for use in the treatment of symptomatic heart failure
DK1478362T3 (en) Combination therapy for acute myocardial infarction
WO2005058280A3 (en) Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
CY1109393T1 (en) THE USE OF ACHIEVEMENT FOR THE PREPARATION OF A MEDICINE THAT INDICATES VASCULATION
BR0000486A (en) Neuropeptide y antagonists
HUP0202339A2 (en) Use of cortisol antagonists in the treatment of heat failure
EA200000909A1 (en) FORM VI 5,6-DICHLOR-2- (ISOPROPYLAMINO) -1- (b-L-RIBOFURANOSIL) -1H-BENZIMIDAZOLE
TR200401952T4 (en) Use of hyaluronidase for prophylaxis and treatment of cardiovascular diseases
CY1105432T1 (en) USES OF THALIPORFIN OR ITS DERIVATIVES IN THE TREATMENT OF HEART DISEASE AND PREPARATION THEREOF
SE9802538D0 (en) New pharmaceutically active compounds
ATE446759T1 (en) USE OF OXCARBAZEPINE TO IMPROVE SLEEP IN PATIENTS SUFFERING FROM CHRONIC PAIN
TR200401036T1 (en) Citalopram for the treatment of high blood pressure.